Profile
| Metric | Value |
|---|---|
| Full Name | ACADIA Pharmaceuticals Inc. |
| Ticker | NASDAQ: ACAD |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Country | United States |
| IPO | |
| Indexes | Not included |
| Website | acadia.com |
| Employees | 653 |
Key Metrics
| Metric | Date | Value |
|---|---|---|
| Price | $26.40 | |
| Price, 1D Change | +0.96% | |
| Market Cap | $4B | |
| - | ||
| PE Ratio | 16.99 | |
| Beta | 0.88 | |
| Revenue | $958M | |
| Revenue, 1Y Change | +31.85% | |
| EPS | $1.36 | |
| EPS, 1Y Change | +463.86% |
Chart
Add series to chart(max: 6)
Series
SUGGESTED SERIES
Events
| Metric | Date | Value |
|---|---|---|
| Next Earnings | ||
| Last Qtr. Earnings | ||
| Last Ann. Earnings | ||
| Last Ex-Dividend | N/A | N/A |
| Next Ex-Dividend | N/A | N/A |
| Last Split | N/A | N/A |
| Next Split | N/A | N/A |
| Last Ticker Change | N/A | N/A |
| Next Ticker Change | N/A | N/A |
🔒 Log In To Unlock Full Data
Estimates
| Metric | Date | Value |
|---|---|---|
| EPS | $1.36 | |
| EPS Estimate | $0.82 | |
| EPS Est. Change | -39.88% | |
| Revenue | $957.80M | |
| Revenue Estimate | $1.08B | |
| Revenue Est. Change | +12.90% | |
| Current Price | $26.40 | |
| Price Target | - | $31.00 |
| Price Tgt. Change | - | +17.42% |
🔒 Log In To Unlock Full Data
EPS
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| -$0.34 | -$0.37 | -10.03% | |
| $0.74 | $1.36 | +84.77% | |
| $0.82 | N/A | -39.88% | |
| $0.81 | N/A | -40.16% |
Revenue
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| $719.19M | $726.44M | +1.01% | |
| $969.41M | $957.80M | -1.20% | |
| $1.08B | N/A | +12.90% | |
| $1.21B | N/A | +25.88% |
🔒 Log In To Unlock Full Data
Performance
| Metric | Date | Value |
|---|---|---|
| Price, 1Y | +51.20% | |
| Price, 3Y | +52.60% | |
| Market Cap, 1Y | +53.45% | |
| Market Cap, 3Y | +59.30% | |
| Revenue, 1Y | +31.85% | |
| Revenue, 3Y | +97.83% | |
| EPS, 1Y | +463.86% | |
| EPS, 3Y | +230.13% |
🔒 Log In To Unlock Full Data
Technical Indicators
| Metric | Date | Value |
|---|---|---|
| Current Price | $26.40 | |
| SMA 200 | $21.92 | |
| SMA 200 vs Price | -16.97% | |
| SMA 50 | $24.90 | |
| SMA 50 vs Price | -5.68% | |
| Beta | 0.88 | |
| ATR | $0.78 | |
| 14-Day RSI | 48.33 | |
| 10-Day Volatility | 26.62% | |
| 1-Year Volatility | 47.74% |
Dividends
| Metric | Date | Value |
|---|---|---|
| N/A | - | |
| Upcoming | N/A | N/A |
| - | ||
| - | ||
| Dividends Paid | $0.00 | |
| Payout Ratio | 0.00% |
🔒 Log In To Unlock Full Data
Income & Profitability
| Metric | Date | Value |
|---|---|---|
| Revenue | $957.80M | |
| EPS | $1.36 | |
| Gross Profit | $860.99M | |
| Gross Margin | 89.89% | |
| Operating Profit | $84.28M | |
| Operating Margin | 8.80% | |
| Net Income | $226.45M | |
| Net Margin | 23.64% | |
| EBITDA | $100.16M |
🔒 Log In To Unlock Full Data
Financial Health
| Metric | Date | Value |
|---|---|---|
| Debt To Equity | 0.00 | |
| Current Ratio | 2.38 | |
| Quick Ratio | 2.32 | |
| - | ||
| F-Score | 4 | |
| Altman Z-Score | 4.88 |
Valuations
| Metric | Date | Value |
|---|---|---|
| PE Ratio | 16.99 | |
| PS Ratio | 4.27 | |
| PB Ratio | 4.87 | |
| EV/EBITDA | 33.88 | |
| Enterprise Value | N/A | - |
Balance Sheet
| Metric | Date | Value |
|---|---|---|
| Book Value | $732.79M | |
| Cash & Equivalents | $755.99M | |
| Total Assets | $1.19B | |
| Current Assets | $938.32M | |
| Total Liabilities | $454.96M | |
| Current Liabilities | $394.87M | |
| Total Debt | $52.00M | |
| Short Term Debt | $9.96M | |
| Accounts Payable | $16.19M |
Expenses
| Metric | Date | Value |
|---|---|---|
| Total Expenses | $873.52M | |
| Operating Expenses | $791.68M | |
| Cost Of Goods Sold | $96.80M | |
| SG&A | $488.43M | |
| D&A | $15.88M | |
| Interest Expense | $0.00 | |
| Income Tax | $31.62M |
Cash Flow
| Metric | Date | Value |
|---|---|---|
| CFO | $157.72M | |
| CFI | -$30.54M | |
| CFF | $6.85M | |
| Capex | $523.00K | |
| Free Cash Flow | $157.20M |
Recent analyst updates
| Metric | Date | Value |
|---|---|---|
| HC Wainwright & Co. | → | |
| Stifel | → | |
| Mizuho | → | |
| JP Morgan | → | |
| RBC Capital | → | |
| Needham | → | |
| Citigroup | ||
| JP Morgan | → | |
| Needham | → | |
| TD Cowen | → |
Analyst sentiment
Institutional ownership
Screeners with ACAD
Data Sources & References
- ACAD Official Website www.acadia.com
- Most Recent Quarterly Report (10-Q) www.sec.gov/Archives/edgar/data/1070494/000119312525267453/0001193125-25-267453-index.htm
- Most Recent Annual Report (10-K) www.sec.gov/Archives/edgar/data/1070494/000095017025029253/0000950170-25-029253-index.htm
- ACAD Profile on Yahoo Finance finance.yahoo.com/quote/ACAD
- ACAD Profile on NASDAQ.com www.nasdaq.com/market-activity/stocks/acad
FAQ
What is the ticker symbol for ACADIA Pharmaceuticals Inc.?
The ticker symbol for ACADIA Pharmaceuticals Inc. is NASDAQ:ACAD
Does ACADIA Pharmaceuticals Inc. pay dividends?
No, ACADIA Pharmaceuticals Inc. does not pay dividends
What sector is ACADIA Pharmaceuticals Inc. in?
ACADIA Pharmaceuticals Inc. is in the Healthcare sector
What industry is ACADIA Pharmaceuticals Inc. in?
ACADIA Pharmaceuticals Inc. is in the Biotechnology industry
What country is ACADIA Pharmaceuticals Inc. based in?
ACADIA Pharmaceuticals Inc. is headquartered in United States
When did ACADIA Pharmaceuticals Inc. go public?
ACADIA Pharmaceuticals Inc. initial public offering (IPO) was on May 27, 2004
Is ACADIA Pharmaceuticals Inc. in the S&P 500?
No, ACADIA Pharmaceuticals Inc. is not included in the S&P 500 index
Is ACADIA Pharmaceuticals Inc. in the NASDAQ 100?
No, ACADIA Pharmaceuticals Inc. is not included in the NASDAQ 100 index
Is ACADIA Pharmaceuticals Inc. in the Dow Jones?
No, ACADIA Pharmaceuticals Inc. is not included in the Dow Jones index
When was ACADIA Pharmaceuticals Inc. last earnings report?
ACADIA Pharmaceuticals Inc.'s most recent earnings report was on November 5, 2025
When does ACADIA Pharmaceuticals Inc. report earnings?
The next expected earnings date for ACADIA Pharmaceuticals Inc. is February 25, 2026